跳至主要内容
临床试验/NCT02090361
NCT02090361已完成不适用

Efficacy of Collagen-elastin Dermal Substitute in the Treatment of Loss of Cutaneous Substances With Skin Grafts

University Hospital, Rouen4 个研究点 分布在 1 个国家目标入组 92 人开始时间: 2014年6月18日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
92
试验地点
4
主要终点
Skin Foldability ( Uf )

研究概览

简要总结

In reconstructive surgery , most losses of cutaneous substance require the use of a thin skin graft . This technique allows epidermization of the defect by applying a thin layer of autologous epidermis. It does not reconstitute the injured skin. Transplants cause retractile scars, adherent to the deep plan, that may require revision surgery . Since a decade , dermal matrices are mainly used in burned skin centers . The collagen -elastin matrix has the advantage to set up in the same operation that the skin graft and contain elastic fibers , two assets which improve the results of skin grafting.

Objective:

Evaluation of the clinical efficacy of the addition of a dermal matrix to skin graft on Skin Foldability, at day 360.

Methodology:

This is a multicenter randomized study (CHU Caen , Amiens, Rouen and Lille)

Conduct of the study :

The transplant will be performed according to the protocol defined between inter -region surgeons. The implementation of the dermal matrix will be in the same surgical technique as thin skin graft ( group 1 ) or the thin skin graft will be performed alone ( group 2) time .

Evaluation Criteria Main : Skin Foldability ( Uf ) assessed grafted site will be compared to the opposite side ungrafted evaluated at Day 360 . Quantitative data will be measured by a cutometer Skin Elasticity Meter 580 (Courage and Khazaba Electronic GmbH).

To achieve the main objective, it is planned to compare the ratio between Uf graft site and the opposite healthy site between two groups: skin + matrix graft , or skin graft only. Thus, the Wilcoxon test for independent samples will be used to settle bilateral formulation between the null hypothesis ( there is no difference between the two groups ) and the alternative hypothesis ( there is a difference between the two groups ) . In determining the overall risk of first species to 5% and the power of this test to detect the 90% expected under the alternative hypothesis difference should be the main criterion for evaluating at least 59 patients in each group so 118 patients total.

Prospect If the contribution of a dermal matrix in loss of skin substances improves skin pliability and reduces pain , functional and aesthetic sequelae grafts thin skin , the dermal matrix may be proposed as a complementary treatment in these indications.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Aged over 18
  • Signed informed consent
  • Patients with loss of cutaneous substance of at least 15 cm2
  • Patient Without bone exposure, vascular, joint or tendon
  • Eligibility for surgical treatment by skin graft
  • Loss of substance trauma (avulsion, burns) or surgery (skin excision)

排除标准

  • Patient with a chronic wound
  • Wound superinfected
  • Patient unable for local or general skin graft
  • Patient with an old or a recent skin injury strictly contralateral to the graft site.
  • Patient unable to consent

研究组 & 干预措施

skin graft with dermal matrix

Experimental

Epidermization of the defect by applying a thin layer of autologous epidermis with addition of a dermal matrix

干预措施: skin graft (Procedure)

skin graft - classic procedure

Placebo Comparator

Epidermization of the defect by applying a thin layer of autologous epidermis

结局指标

主要结局

Skin Foldability ( Uf )

时间窗: Day 360

Skin Foldability ( Uf ) will be assessed on grafted site compared to the opposite side ungrafted at day D360 . Quantitative data will be measured by a cutometer Skin Elasticity Meter 580 (Courage and Khazaba Electronic GmbH).

次要结局

  • Skin Foldability ( Uf )(Day 90)
  • Aesthetic sequelae evaluation(Day 360)
  • Pain on the grafted site(D7)
  • pain on the grafted site(Day 360)
  • Assessment of functional effects(Day 360)
  • tolerance of matriderm use(Day 360)
  • Area healed(Day 30)
  • Assessment of functional effects(Day 30)
  • Assessment of functional effects(Day 90)
  • Assessment of functional effects(Day 180)
  • Aesthetic sequelae evaluation(Day 90)
  • Aesthetic sequelae evaluation(Day 180)
  • Area healed(Day 15)
  • Skin Foldability ( Uf )(Day 180)
  • pain on the grafted site(Day 15)
  • pain on the grafted site(Day 30)
  • pain on the grafted site(Day 90)
  • pain on the grafted site(Day 180)
  • Area healed(Day 7)

研究者

发起方
University Hospital, Rouen
申办方类型
Other
责任方
Sponsor

研究点 (4)

Loading locations...

相似试验